VenoStent

VenoStent is a private, clinical-stage medical device company targeting a critical unmet need in vascular surgery: the failure of dialysis access sites. Its core technology is SelfWrap, a bioabsorbable, 3D-printed perivascular wrap intended to improve the maturation and patency of AV fistulas and grafts. The company has secured FDA Breakthrough Device designation, completed a $16M Series A financing, and initiated a 200-subject US clinical trial, positioning it to address a multi-billion-dollar cost burden for Medicare.

Proprietary 3D-printing platform for bioabsorbable, finely-tuned polymer wraps designed for perivascular application to provide controlled mechanical support and inhibit pathological vessel remodeling.

The competitive landscape for dialysis access support includes off-label use of bare-metal or covered stents for treating stenosis, but there are few dedicated, FDA-approved devices for proactive prevention of failure at the time of access creation. VenoStent's primary competition is the current standard of care (no proactive support) and surgical technique optimization. If successful, SelfWrap could establish a new device category, though it may later face competition from other companies developing external support devices.